USANA Health Sciences (NYSE:USNA) Issues FY 2024 Earnings Guidance

USANA Health Sciences (NYSE:USNA) updated its FY 2024 earnings guidance on Tuesday. The company provided EPS guidance of 2.400-2.550 for the period, compared to the consensus EPS estimate of 2.780. The company issued revenue guidance of $850.0 million-$880.0 million, compared to the consensus revenue estimate of $883.5 million.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on USNA. DA Davidson decreased their target price on shares of USANA Health Sciences from $46.00 to $38.00 and set a neutral rating on the stock in a research report on Thursday. StockNews.com lowered shares of USANA Health Sciences from a strong-buy rating to a buy rating in a research report on Wednesday.

USANA Health Sciences Stock Performance

USNA traded up $0.17 during trading on Friday, hitting $42.01. The stock had a trading volume of 3,070 shares, compared to its average volume of 79,800. The stock has a 50 day simple moving average of $46.27 and a two-hundred day simple moving average of $47.07. USANA Health Sciences has a twelve month low of $40.51 and a twelve month high of $68.00. The company has a market capitalization of $800.29 million, a PE ratio of 13.03, a PEG ratio of 1.50 and a beta of 0.90.

USANA Health Sciences (NYSE:USNA) last issued its earnings results on Tuesday, July 23rd. The company reported $0.54 EPS for the quarter, missing analysts’ consensus estimates of $0.65 by ($0.11). USANA Health Sciences had a return on equity of 11.13% and a net margin of 6.29%. The firm had revenue of $212.87 million for the quarter, compared to analysts’ expectations of $218.64 million. During the same period last year, the firm earned $0.89 earnings per share. On average, equities research analysts anticipate that USANA Health Sciences will post 2.48 EPS for the current year.

Insiders Place Their Bets

In other USANA Health Sciences news, major shareholder Myron W. Wentz sold 13,496 shares of the business’s stock in a transaction that occurred on Friday, June 14th. The shares were sold at an average price of $45.03, for a total transaction of $607,724.88. Following the completion of the transaction, the insider now owns 7,864,345 shares in the company, valued at approximately $354,131,455.35. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CFO G Doug Iiekking sold 5,198 shares of the company’s stock in a transaction on Tuesday, May 7th. The shares were sold at an average price of $44.76, for a total value of $232,662.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Myron W. Wentz sold 13,496 shares of the stock in a transaction on Friday, June 14th. The stock was sold at an average price of $45.03, for a total transaction of $607,724.88. Following the sale, the insider now owns 7,864,345 shares of the company’s stock, valued at approximately $354,131,455.35. The disclosure for this sale can be found here. Insiders sold 31,591 shares of company stock worth $1,458,098 in the last 90 days. Corporate insiders own 0.33% of the company’s stock.

About USANA Health Sciences

USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.